Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

Learn more about:
Related Clinical Trial
Tricaprilin Infantile Spasms Pilot Study Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm Sabril Patient Registry Epilepsy Phenome/Genome Project Metabolic Abnormalities in Children With Epilepsy Genetics of Severe Early Onset Epilepsies A Novel Approach to Infantile Spasms Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms Prednisolone in Infantile Spasms- High Dose Versus Usual Dose Addition of Pyridoxine to Prednisolone in Infantile Spasms Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) Open-label Extension to Protocol 1042-0500 Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH) Evaluation of Neuroinflammation in Children With Infantile Spasms Molecular Genetics in Infantile Spasms Genetic Studies in Patients and Families With Infantile Spasms Use of the Modified Atkins Diet in Infantile Spasms Treatment of Refractory Infantile Spasms With Fenfluramine A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

Brief Title

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

Official Title

A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study

Brief Summary

      This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase,
      and an open-label extension phase. The open-label extension phase only will be described in
      this record. All participants will receive GWP42003-P.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)

Secondary Outcome

 Number of Participants Free of Clinical Spasms

Condition

Infantile Spasms

Intervention

GWP42003-P

Study Arms / Comparison Groups

 GWP42003-P
Description:  Administered orally, up to the target dose recommended by the data safety monitoring committee.
Participants continue at the target dose, or the highest tolerated dose up to the target dose, for a total of 12 months' treatment.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

9

Start Date

May 12, 2017

Completion Date

June 13, 2019

Primary Completion Date

June 13, 2019

Eligibility Criteria

        Only participants who completed the pilot or pivotal phases of the trial may proceed to
        take part in this open-label extension phase of the trial.

        Key eligibility criteria for the blinded phase were as follows:

        Key Inclusion Criteria:

          -  Participant is diagnosed with IS and has failed to respond adequately following
             treatment with 1 or more approved IS therapies.

        Key Exclusion Criteria:

          -  Participant is currently taking or has taken clobazam or any mammalian target of
             rapamycin (mTOR) inhibitor within the 2 weeks prior to the screening visit.

          -  Participant has a QT interval, corrected for heart rate with Bazett's formula (QTcB),
             of 460 msec or greater on ECG.

          -  Participant's caregiver is currently giving or has given recreational or medicinal
             cannabis, or synthetic cannabinoid-based medications, within the 1 month prior to the
             screening visit.

          -  Participant's caregiver is unwilling to abstain from giving the participant (including
             the participant's mother abstaining themselves, if breastfeeding)recreational or
             medicinal cannabis, or synthetic cannabinoid-based medications (other than the study
             drug) during the trial.

          -  Participant has any known or suspected hypersensitivity to cannabinoids or any of the
             excipients of the study drug, such as sesame oil.

          -  Participant has significantly impaired hepatic function at the screening visit.

          -  Participant has received an investigational medicinal product as part of a clinical
             trial within a minimum of 5 half-lives prior to the screening visit.
      

Gender

All

Ages

1 Month - 24 Months

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Poland

Location Countries

Poland

Administrative Informations


NCT ID

NCT02954887

Organization ID

GWEP15100 Open-label Extension

Secondary IDs

2015-004904-50

Responsible Party

Sponsor

Study Sponsor

GW Research Ltd


Study Sponsor

, , 


Verification Date

July 2020